|
|
Advax-CpG55.2 |
|
Vaxjo ID |
120 |
|
Vaccine Adjuvant Name |
Advax-CpG55.2 |
|
Adjuvant VO ID |
VO_0005324
|
|
Description |
An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2. |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Adelaid, Australia |
|
Host Species for Testing |
Human |
|
Components |
inulin-based formulations (Advax) containing a CpG oligodeoxynucleotide (ODN |
|
Storage |
Store refrigerated at 2-8C. Do not freeze |
|
Preparation |
"delta inulin polysaccharide is formulated with the TLR9 agonist CpG oligodeoxynucleotides (CpG ODN)" |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 9 (TLR9). Induces Th1-biased immune profile. Dendritic cell activation, chemotaxis |
| References |
(Petrovsky, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=38]
Blake et al., 2021: Blake S, Bremer PT, Zhou B, Petrovsky N, Smith LC, Hwang CS, Janda KD. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability. Molecular pharmaceutics. 2021; 18(1); 228-235. [PubMed: 33301675].
Tabarsi et al., 2022: Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Roshanzamir K, Bayatani B, Taheri A, Petrovsky N, Li L, Barati S. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022; 28(9); 1263-1271. [PubMed: 35436611].
|
|
